{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:36:56Z","timestamp":1782283016805,"version":"3.54.5"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["Chamada 58\/2022 \u201cInstituto Nacional de Ci\u00eancia e Tecnologia do Sangue\u2014INCT do Sangue\u201d. #382025\/2023-7"],"award-info":[{"award-number":["Chamada 58\/2022 \u201cInstituto Nacional de Ci\u00eancia e Tecnologia do Sangue\u2014INCT do Sangue\u201d. #382025\/2023-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["Chamada 58\/2022 \u201cInstituto Nacional de Ci\u00eancia e Tecnologia do Sangue\u2014INCT do Sangue\u201d. #382025\/2023-7"],"award-info":[{"award-number":["Chamada 58\/2022 \u201cInstituto Nacional de Ci\u00eancia e Tecnologia do Sangue\u2014INCT do Sangue\u201d. #382025\/2023-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["UNIVERSAL CNPq\/MCTI\/FNDCT N\u00ba 18\/2021 - Faixa B - Grupos Consolidados - PROCESSO N\u00ba 422726\/2021-4 - An\u00e1lise da via STING de pacientes com S\u00edndrome Mielodispl\u00e1sica prim\u00e1ria e de modelos de les\u00e3o de fita dupla de DNA secund\u00e1ria a quimioter\u00e1picos em pacientes oncol\u00f3gicos e camundongos C57BL\/6"],"award-info":[{"award-number":["UNIVERSAL CNPq\/MCTI\/FNDCT N\u00ba 18\/2021 - Faixa B - Grupos Consolidados - PROCESSO N\u00ba 422726\/2021-4 - An\u00e1lise da via STING de pacientes com S\u00edndrome Mielodispl\u00e1sica prim\u00e1ria e de modelos de les\u00e3o de fita dupla de DNA secund\u00e1ria a quimioter\u00e1picos em pacientes oncol\u00f3gicos e camundongos C57BL\/6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02376-8","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:02:14Z","timestamp":1713956534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of the STING\u00a0pathway in myeloid neoplasms: a prospero-registered systematic review of principal hurdles of STING\u00a0on the road to the clinical practice"],"prefix":"10.1007","volume":"41","author":[{"given":"Leticia Rodrigues","family":"Sampaio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Dyllan Barbosa","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Vitor Caetano","family":"Goes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Pinheiro Martins","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"de Paula Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara Magna","family":"de Lima Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Taiane Germano","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Lopes","family":"Ribeiro-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Maria Meira","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Feitosa","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"10","key":"2376_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","volume":"12","author":"SM Crusz","year":"2015","unstructured":"Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584\u201396.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2376_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"1","key":"2376_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"11","key":"2376_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759\u201371.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2376_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41568-022-00462-5","volume":"22","author":"SM Man","year":"2022","unstructured":"Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer. 2022;22(7):397\u2013413.","journal-title":"Nat Rev Cancer"},{"issue":"7213","key":"2376_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674\u20138.","journal-title":"Nature"},{"issue":"9","key":"2376_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21(9):501\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2376_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4049\/jimmunol.1601999","volume":"199","author":"B Larkin","year":"2017","unstructured":"Larkin B, Ilyukha V, Sorokin M, Buzdin A, Vannier E, Poltorak A. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J Immunol. 2017;199(2):397\u2013402.","journal-title":"J Immunol"},{"issue":"1","key":"2376_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.it.2017.07.013","volume":"39","author":"KW Ng","year":"2018","unstructured":"Ng KW, Marshall EA, Bell JC, Lam WL. cGAS-STING and cancer: dichotomous roles in tumor immunity and development. Trends Immunol. 2018;39(1):44\u201354.","journal-title":"Trends Immunol"},{"issue":"1","key":"2376_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152.","journal-title":"Mol Cancer"},{"issue":"12","key":"2376_CR11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363.","journal-title":"Nat Cancer"},{"issue":"10","key":"2376_CR12","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1002\/eji.201344407","volume":"44","author":"H Lemos","year":"2014","unstructured":"Lemos H, Huang L, McGaha TL, Mellor AL. Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol. 2014;44(10):2847\u201353.","journal-title":"Eur J Immunol"},{"issue":"10","key":"2376_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142\u20139.","journal-title":"Nat Immunol"},{"issue":"214","key":"2376_CR14","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2002521","volume":"5","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5(214):ra20.","journal-title":"Sci Signal"},{"issue":"6","key":"2376_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cytogfr.2014.05.003","volume":"25","author":"Y Ran","year":"2014","unstructured":"Ran Y, Shu HB, Wang YY. MITA\/STING: a central and multifaceted mediator in innate immune response. Cytokine Growth Factor Rev. 2014;25(6):631\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"2376_CR16","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1128\/JVI.00037-14","volume":"88","author":"T Abe","year":"2014","unstructured":"Abe T, Barber GN. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-\u03baB activation through TBK1. J Virol. 2014;88(10):5328\u201341.","journal-title":"J Virol"},{"issue":"7689","key":"2376_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature25432","volume":"553","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe\u2019er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, Cantley LC. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467\u201372.","journal-title":"Nature"},{"key":"2376_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","volume":"14","author":"X An","year":"2019","unstructured":"An X, Zhu Y, Zheng T, Wang G, Zhang M, Li J, Ji H, Li S, Yang S, Xu D, Li Z, Wang T, He Y, Zhang L, Yang W, Zhao R, Hao D, Li X. An analysis of the expression and association with immune cell infiltration of the cGAS\/STING pathway in pan-cancer. Mol Ther Nucleic Acids. 2019;14:80\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2376_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","volume":"14","author":"T Xia","year":"2016","unstructured":"Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 2016;14(2):282\u201397.","journal-title":"Cell Rep"},{"issue":"2","key":"2376_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbadis.2013.11.006","volume":"1842","author":"K Bhatelia","year":"2014","unstructured":"Bhatelia K, Singh A, Tomar D, Singh K, Sripada L, Chagtoo M, Prajapati P, Singh R, Godbole MM, Singh R. Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-\u03baB induced cell death. Biochim Biophys Acta. 2014;1842(2):144\u201353.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2376_CR21","doi-asserted-by":"publisher","first-page":"12739","DOI":"10.1038\/s41598-022-17122-1","volume":"12","author":"R Takayanagi-Hara","year":"2022","unstructured":"Takayanagi-Hara R, Sawada Y, Sugino H, Minokawa Y, Kawahara-Nanamori H, Itamura M, Tashiro T, Kaneoka A, Saito-Sasaki N, Yamamoto K, Okada E. STING expression is an independent prognostic factor in patients with mycosis fungoides. Sci Rep. 2022;12(1):12739.","journal-title":"Sci Rep"},{"issue":"7","key":"2376_CR22","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the world health organization classification of haematolymphoid tumours myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"key":"2376_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-12-304","volume":"12","author":"A Murati","year":"2012","unstructured":"Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12:304.","journal-title":"BMC Cancer"},{"issue":"3","key":"2376_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/XEB.0000000000000062","volume":"13","author":"C Lockwood","year":"2015","unstructured":"Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015;13(3):179\u201387.","journal-title":"Int J Evid Based Healthc"},{"key":"2376_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"3","key":"2376_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"5","key":"2376_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000468","volume":"4","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R. Chronic Myeloid Leukemia in 2020. Hemasphere. 2020;4(5): e468.","journal-title":"Hemasphere"},{"issue":"1","key":"2376_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2376_CR29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u201368.","journal-title":"Leuk Res"},{"issue":"1","key":"2376_CR30","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1038\/s41598-023-33852-2","volume":"13","author":"H Hiroki","year":"2023","unstructured":"Hiroki H, Ishii Y, Piao J, Namikawa Y, Masutani M, Honda H, Akahane K, Inukai T, Morio T, Takagi M. Targeting Poly(ADP)ribose polymerase in BCR\/ABL1-positive cells. Sci Rep. 2023;13(1):7588.","journal-title":"Sci Rep"},{"issue":"9936","key":"2376_CR31","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","volume":"383","author":"L Ad\u00e8s","year":"2014","unstructured":"Ad\u00e8s L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239\u201352.","journal-title":"Lancet"},{"issue":"14","key":"2376_CR32","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358\u201374.","journal-title":"N Engl J Med"},{"issue":"1","key":"2376_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","volume":"8","author":"H Li","year":"2022","unstructured":"Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat Rev Dis Primers. 2022;8(1):74.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2376_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/hon.2608","volume":"37","author":"JC de Sousa","year":"2019","unstructured":"de Sousa JC, da N\u00f3brega IM, Costa MB, Farias IR, de Paula BD, de Oliveira RT, Fukutani KF, Thom\u00e9 CH, da Silva Martinelli CM, Myajima F, Vidal DO, Magalh\u00e3es SMM, Figueiredo-Pontes LL, Pinheiro RF. Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematol Oncol. 2019;37(4):523\u20136.","journal-title":"Hematol Oncol"},{"issue":"10","key":"2376_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12032-017-1023-1","volume":"34","author":"AG de Matos","year":"2017","unstructured":"de Matos AG, Ribeiro Junior HL, de Paula BD, Okubo BM, de Sousa JC, Barbosa MC, de Castro MF, Gon\u00e7alves RP, Pinheiro RF, Magalh\u00e3es SMM. Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome. Med Oncol. 2017;34(10):168.","journal-title":"Med Oncol"},{"key":"2376_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","volume":"122","author":"C Wang","year":"2018","unstructured":"Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, Li M, Zhan X, Li W. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123\u201332.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"2376_CR37","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.19.01823","volume":"38","author":"S Winter","year":"2020","unstructured":"Winter S, Shoaie S, Kordasti S, Platzbecker U. Integrating the \u201cImmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol. 2020;38(15):1723\u201335.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2376_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12032-021-01466-1","volume":"38","author":"RTG de Oliveira","year":"2021","unstructured":"de Oliveira RTG, Cordeiro JVA, Vitoriano BF, de Lima Melo MM, Sampaio LR, de Paula BD, Magalh\u00e3es SMM, Pinheiro RF. ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis. Med Oncol. 2021;38(3):27.","journal-title":"Med Oncol"},{"issue":"15","key":"2376_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159430","volume":"7","author":"AF McLemore","year":"2022","unstructured":"McLemore AF, Hou HA, Meyer BS, Lam NB, Ward GA, Aldrich AL, Rodrigues MA, Vedder A, Zhang L, Padron E, Vincelette ND, Sallman DA, Abdel-Wahab O, List AF, McGraw KL. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS\/STING\/NLRP3 axis in myelodysplastic syndromes. JCI Insight. 2022;7(15): e159430.","journal-title":"JCI Insight"},{"issue":"12","key":"2376_CR40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"3","key":"2376_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jcm5030033","volume":"5","author":"JN Saultz","year":"2016","unstructured":"Saultz JN, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med. 2016;5(3):33.","journal-title":"J Clin Med"},{"issue":"5","key":"2376_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2376_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138(3):234\u201345.","journal-title":"Blood"},{"issue":"27","key":"2376_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123227119","volume":"119","author":"AA Kogan","year":"2022","unstructured":"Kogan AA, Topper MJ, Dellomo AJ, Stojanovic L, McLaughlin LJ, Creed TM, Eberly CL, Kingsbury TJ, Baer MR, Kessler MD, Baylin SB, Rassool FV. Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia. Proc Natl Acad Sci USA. 2022;119(27): e2123227119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2376_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110856","volume":"39","author":"RS Singh","year":"2022","unstructured":"Singh RS, Vidhyasagar V, Yang S, Arna AB, Yadav M, Aggarwal A, Aguilera AN, Shinriki S, Bhanumathy KK, Pandey K, Xu A, Rapin N, Bosch M, DeCoteau J, Xiang J, Vizeacoumar FJ, Zhou Y, Misra V, Matsui H, Ross SR, Wu Y. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep. 2022;39(8): 110856.","journal-title":"Cell Rep"},{"issue":"1","key":"2376_CR46","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1038\/s41598-022-12449-1","volume":"12","author":"C Song","year":"2022","unstructured":"Song C, Liu D, Liu S, Li D, Horecny I, Zhang X, Li P, Chen L, Miller M, Chowdhury R, Issa M, Shen R, Yan Y, Zhang F, Zhang L, Zhang L, Bai C, Feng J, Zhuang L, Zhang R, Li J, Wilkinson H, Liu J, Tao W. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis. Sci Rep. 2022;12(1):8579.","journal-title":"Sci Rep"},{"issue":"11","key":"2376_CR47","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.celrep.2016.05.023","volume":"15","author":"E Curran","year":"2016","unstructured":"Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M, Kline J. STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep. 2016;15(11):2357\u201366.","journal-title":"Cell Rep"},{"issue":"5","key":"2376_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974\u201386.","journal-title":"Cell"},{"issue":"5","key":"2376_CR49","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, O\u2019Brien C, De Carvalho DD. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373.","journal-title":"Cell"},{"issue":"1","key":"2376_CR50","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1038\/s41467-020-19464-8","volume":"11","author":"SK Saini","year":"2020","unstructured":"Saini SK, \u00d8rskov AD, Bjerregaard AM, Unnikrishnan A, Holmberg-Thyd\u00e9n S, Borch A, Jensen KV, Anande G, Bentzen AK, Marquard AM, Tamhane T, Treppendahl MB, Gang AO, Dufva IH, Szallasi Z, Ternette N, Pedersen AG, Eklund AC, Pimanda J, Gr\u00f8nb\u00e6k K, Hadrup SR. Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nat Commun. 2020;11(1):5660.","journal-title":"Nat Commun"},{"issue":"6","key":"2376_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41579-019-0189-2","volume":"17","author":"WE Johnson","year":"2019","unstructured":"Johnson WE. Origins and evolutionary consequences of ancient endogenous retroviruses. Nat Rev Microbiol. 2019;17(6):355\u201370.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"2376_CR52","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/v12080884","volume":"12","author":"FK Geis","year":"2020","unstructured":"Geis FK, Goff SP. Silencing and transcriptional regulation of endogenous retroviruses: an overview. Viruses. 2020;12(8):884.","journal-title":"Viruses"},{"issue":"2","key":"2376_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","volume":"110","author":"M Duchmann","year":"2019","unstructured":"Duchmann M, Itzykson R. Clinical update on hypomethylating agents. Int J Hematol. 2019;110(2):161\u20139.","journal-title":"Int J Hematol"},{"key":"2376_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650473","volume":"11","author":"C Kordella","year":"2021","unstructured":"Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Front Oncol. 2021;11: 650473.","journal-title":"Front Oncol"},{"issue":"1","key":"2376_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13148-023-01493-x","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Min S, Kim D, Park J, Park E, Koh Y, Shin DY, Kim TK, Byun JM, Yoon SS, Hong J. Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation. Clin Epigenetics. 2023;15(1):75.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2376_CR56","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41467-023-37217-1","volume":"14","author":"R Falahat","year":"2023","unstructured":"Falahat R, Berglund A, Perez-Villarroel P, Putney RM, Hamaidi I, Kim S, Pilon-Thomas S, Barber GN, Mul\u00e9 JJ. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat Commun. 2023;14(1):1573.","journal-title":"Nat Commun"},{"issue":"11","key":"2376_CR57","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.tig.2018.08.003","volume":"34","author":"B Tiwari","year":"2018","unstructured":"Tiwari B, Jones AE, Abrams JM. Transposons, p53 and genome security. Trends Genet. 2018;34(11):846\u201355.","journal-title":"Trends Genet"},{"issue":"16","key":"2376_CR58","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","volume":"7","author":"HJ Abel","year":"2023","unstructured":"Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, Fronick CC, Fulton RS, Heath SE, Tarnawsky SP, Nonavinkere Srivatsan S, Duncavage EJ, Schroeder MC, Payton JE, Spencer DH, Walter MJ, Westervelt P, DiPersio JF, Ley TJ, Link DC. Genomic landscape of TP53-mutated myeloid malignancies. Blood Adv. 2023;7(16):4586\u201398.","journal-title":"Blood Adv"},{"issue":"9","key":"2376_CR59","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood.2022018236","volume":"141","author":"D Hiwase","year":"2023","unstructured":"Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023;141(9):1087\u201391.","journal-title":"Blood"},{"issue":"10","key":"2376_CR60","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Sol\u00e9 F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, J\u00e4dersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellstr\u00f6m-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549\u201356.","journal-title":"Nat Med"},{"issue":"24","key":"2376_CR61","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3390\/cancers13246385","volume":"13","author":"CM Csizmar","year":"2021","unstructured":"Csizmar CM, Saliba AN, Swisher EM, Kaufmann SH. PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers (Basel). 2021;13(24):6385.","journal-title":"Cancers (Basel)"},{"key":"2376_CR62","doi-asserted-by":"crossref","unstructured":"Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Verg\u00e9 V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Ad\u00e8s L, Fenaux P, R\u00e9cher C, Dombret H, Pag\u00e8s A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. 2022 Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. Clin Cancer Res. 28(23): 5211\u20135220.","DOI":"10.1158\/1078-0432.CCR-22-1622"},{"issue":"1","key":"2376_CR63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ejh.12966","volume":"100","author":"HL Ribeiro Jr","year":"2018","unstructured":"Ribeiro HL Jr, Maia ARS, de Oliveira RTG, Dos Santos AWA, Costa MB, Farias IR, Borges DP, Magalh\u00e3es SMM, Pinheiro RF. Expression of DNA repair genes is important molecular findings in CD34 + stem cells of myelodysplastic syndrome. Eur J Haematol. 2018;100(1):108\u20139.","journal-title":"Eur J Haematol"},{"issue":"22","key":"2376_CR64","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","volume":"5","author":"CN Kontandreopoulou","year":"2021","unstructured":"Kontandreopoulou CN, Diamantopoulos PT, Tiblalexi D, Giannakopoulou N, Viniou NA. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5(22):4794\u2013805.","journal-title":"Blood Adv"},{"issue":"3","key":"2376_CR65","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/eji.201344127","volume":"44","author":"N Bhat","year":"2014","unstructured":"Bhat N, Fitzgerald KA. Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur J Immunol. 2014;44(3):634\u201340.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2376_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13238-016-0303-4","volume":"8","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Zhu Y, Liu ZJ, Ouyang S. The emerging roles of the DDX41 protein in immunity and diseases. Protein Cell. 2017;8(2):83\u20139.","journal-title":"Protein Cell"},{"key":"2376_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992340","volume":"12","author":"S Shinriki","year":"2022","unstructured":"Shinriki S, Matsui H. Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis. Front Oncol. 2022;12: 992340.","journal-title":"Front Oncol"},{"issue":"5","key":"2376_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, M\u00fcller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141(5):534\u201349.","journal-title":"Blood"},{"issue":"12","key":"2376_CR69","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/ni.2460","volume":"13","author":"K Parvatiyar","year":"2012","unstructured":"Parvatiyar K, Zhang Z, Teles RM, Ouyang S, Jiang Y, Iyer SS, Zaver SA, Schenk M, Zeng S, Zhong W, Liu ZJ, Modlin RL, Liu YJ, Cheng G. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol. 2012;13(12):1155\u201361.","journal-title":"Nat Immunol"},{"issue":"1","key":"2376_CR70","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: STING agonists in cancer therapy. Oncoimmunology. 2020;9(1):1777624.","journal-title":"Oncoimmunology"},{"issue":"22","key":"2376_CR71","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1200\/JCO.2011.35.0660","volume":"29","author":"PN Lara Jr","year":"2011","unstructured":"Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(22):2965\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2376_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.19594","volume":"13","author":"C Aggarwal","year":"2012","unstructured":"Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012;13(5):247\u201363.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2376_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1517\/13543784.17.1.23","volume":"17","author":"MJ McKeage","year":"2008","unstructured":"McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs. 2008;17(1):23\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"Supplement 1","key":"2376_CR74","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1182\/blood-2022-157935","volume":"140","author":"RS Maynard","year":"2022","unstructured":"Maynard RS, Hellmich C, Hampton K, Jibril A, Bowles KM, Rushworth SA. Sting agonists activate bone marrow macrophages and synergise with anti-CD47 blockade improving survival in animal models of acute myeloid leukemia. Blood. 2022;140(Supplement 1):9096\u20136.","journal-title":"Blood"},{"issue":"Suppl","key":"2376_CR75","doi-asserted-by":"publisher","first-page":"e451088e","DOI":"10.1097\/01.HS9.0000974372.45108.8e","volume":"7","author":"P Montesinos","year":"2023","unstructured":"Montesinos P, Al-Ali HK, Dominguez JMA, Jentzsch M, Lavrencic M, Martelli MP, R\u00f6llig C, Sica S, Riham I, Yablonski K, Wang T, Mahmood Z, Koenen G, Schmidt H, Yang J, Yee K. PB1887: STING agonist for the treatment of relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a first-in-clinic phase 1 study of GSK3745417. Hemasphere. 2023;7(Suppl):e451088e.","journal-title":"Hemasphere"},{"issue":"10","key":"2376_CR76","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/cells8101228","volume":"8","author":"C Hong","year":"2019","unstructured":"Hong C, Tijhuis AE, Foijer F. The cGAS paradox: contrasting roles for cGAS-STING pathway in chromosomal instability. Cells. 2019;8(10):1228.","journal-title":"Cells"},{"issue":"1","key":"2376_CR77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10(1):26\u201339.","journal-title":"Cancer Discov"},{"key":"2376_CR78","volume":"14","author":"KA Abuelgasim","year":"2020","unstructured":"Abuelgasim KA, Albuhayri B, Munshi R, Mugairi AA, Alahmari B, Gmati G, Salama H, Alzahrani M, Alhejazi A, Alaskar A, Damlaj M. Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. Leuk Res Rep. 2020;14: 100206.","journal-title":"Leuk Res Rep"},{"issue":"9","key":"2376_CR79","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328(9):872\u201380.","journal-title":"JAMA"},{"issue":"7","key":"2376_CR80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201544","volume":"218","author":"JJ Trowbridge","year":"2021","unstructured":"Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218(7): e20201544.","journal-title":"J Exp Med"},{"issue":"24","key":"2376_CR81","first-page":"00013","volume":"S0037\u20131963","author":"L Guarnera","year":"2024","unstructured":"Guarnera L, Jha BK. TET2 mutation as prototypic clonal hematopoiesis lesion. Semin Hematol. 2024;S0037\u20131963(24):00013\u201321.","journal-title":"Semin Hematol"},{"key":"2376_CR82","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","volume":"34","author":"Y Liu","year":"2019","unstructured":"Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Rev. 2019;34:67\u201383.","journal-title":"Blood Rev"},{"issue":"10","key":"2376_CR83","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/bioengineering10101228","volume":"10","author":"L Guarnera","year":"2023","unstructured":"Guarnera L, Bravo-Perez C, Visconte V. Immunotherapy in acute myeloid leukemia: a literature review of emerging strategies. Bioengineering (Basel). 2023;10(10):1228.","journal-title":"Bioengineering (Basel)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02376-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T04:14:48Z","timestamp":1718252088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":83,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02376-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"128"}}